(Q38037156)

27 August 2017

title

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease (English)

1 reference

27 August 2017

0 references

Karl Herholz

1

1 reference

27 August 2017

publication date

1 August 2012

1 reference

27 August 2017

published in

Biomarkers in Medicine

1 reference

27 August 2017

volume

6

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

431-439

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

27 August 2017

cites work

1 reference

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

Disease-modifying trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

Relation between physiological function and energy metabolism in the central nervous system

21 January 2018

1 reference

Neuronal-glial glucose oxidation and glutamatergic-GABAergic function.

21 January 2018

1 reference

Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene

21 January 2018

1 reference

Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease

21 January 2018

1 reference

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

21 January 2018

1 reference

Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease

21 January 2018

1 reference

Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment

21 January 2018

1 reference

Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study.

21 January 2018

1 reference

Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease.

21 January 2018

1 reference

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

21 January 2018

1 reference

Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature

21 January 2018

1 reference

Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping

21 January 2018

1 reference

Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

21 January 2018

1 reference

New computer-aided diagnosis of dementia using positron emission tomography: brain regional sensitivity-mapping method

21 January 2018

1 reference

Characterizing Alzheimer's disease using a hypometabolic convergence index

21 January 2018

1 reference

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

21 January 2018

1 reference

Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison

21 January 2018

1 reference

Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay

21 January 2018

1 reference

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease

21 January 2018

1 reference

Comparing predictors of conversion and decline in mild cognitive impairment

21 January 2018

1 reference

Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease

21 January 2018

1 reference

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

21 January 2018

1 reference

Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.

21 January 2018

1 reference

The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update

21 January 2018

1 reference

Neurovascular regulation in the normal brain and in Alzheimer's disease

21 January 2018

1 reference

Functional connectivity tracks clinical deterioration in Alzheimer's disease

21 January 2018

1 reference

Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease

21 January 2018

1 reference

Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease

21 January 2018

1 reference

Report of the task force on designing clinical trials in early (predementia) AD.

21 January 2018

1 reference

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease

21 January 2018

1 reference

False discovery rate revisited: FDR and topological inference using Gaussian random fields.

21 January 2018

1 reference

Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography.

21 January 2018

1 reference

Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study

21 January 2018

1 reference

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial

21 January 2018

1 reference

Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography

21 January 2018

1 reference

Comparison of eight methods for the estimation of the image-derived input function in dynamic [(18)F]-FDG PET human brain studies

21 January 2018

1 reference

Brain metabolic effects of Neotrofin in patients with Alzheimer's disease

21 January 2018

1 reference

Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.

21 January 2018

1 reference

Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment.

21 January 2018

1 reference

Integrating ADNI results into Alzheimer's disease drug development programs

21 January 2018

1 reference

Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study

21 January 2018

1 reference

Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

21 January 2018

1 reference

Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study

21 January 2018

1 reference

Statistical parametric maps in functional imaging: A general linear approach

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.12.51

1 reference

27 August 2017

1 reference